The Exosome Diagnostics, Therapeutics and Research Tools Market is estimated to be worth USD 320.52 million in 2024 and is anticipated to reach USD 1274.09 million by 2029, with a CAGR of 41.2% during the forecast period.
The Exosome Diagnostics, Therapeutics and Research Tools Market is witnessing a considerable rise because of developments in exosome study, the recognition of biosignatures and therapeutic agents and the progressive adoption of precision drug techniques. Furthermore, the industry players are increasingly investing and are also entering into tactical partnerships which is generating positive outcomes for the market. Apart from this, better understanding and acceptance also add to the swift market growth. For instance, in June 2023, Evox Therapeutics Ltd purchased an engEx-AAV tech platform made by Codiak Bioscience and obtained sole rights for engineering and producing. This provides them with quick transfer from exosome to adeno-associated virus (AAV for improved supply and expression in early-stage clinical versions while protecting from offsetting antibodies.
The exosome diagnostics, therapeutics and research tools market growth is propelled by drivers including the rising number of partnerships and commercialization projects, the uprising of exosome-based liquid biopsy and the increasing trend of subcontracting its production activities.
The expanding prospects of exosome-based liquid biopsy is one of the main propellants pushing forward the market growth. It is widely used in clinical studies which is basically due to its constancy and capability to hold genetic matter like miRNA, mRNA and DNA. Also, these are appropriate for diagnostics uses as it is an innovative source of biosignatures. Lately, they have arisen as a potential tool for liquid biopsy providing non-surgical choices for treatment response tracking, prognosis and disease diagnosis in both transmissible and non-transmissible infections or illnesses.
Apart from this, another factor driving the market growth is the rising need for molecular diagnosis. Exosome analysis, for example, is rapidly getting popular for its precision and capability to deliver in-depth information about a patient's wellbeing.
Additionally, the development of the next generation of therapeutics throughout the key treatment fields in Respiratory and Immunology, Renal and Metabolism, Oncology and Cardiovascular is expected to contribute to the expansion of the market in the coming years.
The rising cost of healthcare services is presenting potential prospects for the exosome diagnostics, therapeutics and research tools market. The healthcare industry is under stress to lower the prices of medical services to improve their approachability among the increasing patient incidences. For this purpose, laboratories are accepting solutions that are incorporated with data processing. This assists in accelerating efficiency with the support of existing resources.
Additionally, the market is also expected to grow tremendously in the field of digital therapeutics. This is quickly gaining traction which merges technology and medical services to provide unique and research-supported therapies to patients.
Strict government laws and guidelines along with the requirement of extensive understanding are decreasing the exosome diagnostics, therapeutics and research tools market growth rate. At times, getting permission from public authorities for freshly developed approaches and medicines is the main problem for drug companies and often consumes great time. Also, the difficulty in separating exosomes is another problem for the industry players. It needs a sufficient amount of period, substantial and consistent financial support, laboratories with state-of-the-art abilities and trained staff. Hence, the absence of qualified specialists in the domain is expected to stagnate the rise of the Exosome Diagnostic and Therapeutic Market. Furthermore, the loss of significant investment in case of project failure.
The Exosome Diagnostics, Therapeutics and Research Tools Market growth is hindered by the lack of sufficient protocols. This is causing a considerable delay in the exosome development and manufacturing thereafter. Moreover, despite the remarkable rise of digital therapeutics, the major obstacle to the industry’s progress is the approachability and employability of online interventions. For this purpose, they are required to be customer-friendly and smoothly incorporated into patient’s routine lives. Besides this, solving security and data privacy issues is another important aspect of creating trust in online therapeutics.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Type, Products & Services, Application, End User and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
Bio-Techne (US), ILIAS Biologics Inc. (Korea), NanoFCM Inc. (UK), Evox Therapeutics (US), System Biosciences, LLC. (US), Capricor Therapeutics, Inc. (US), Capital Biosciences, Inc. (US), Exonox Biosciences, Inc. (Taiwan), AMSBIO (UK), INOVIQ (Australia), Kimera Labs (US) NanoSomiX, Inc. (US). |
The diagnostics segment spearheads the category and captures a significant portion of the Exosome Diagnostics, Therapeutics and Research Tools Market share. This can be attributed to the considerable application of exosomes for diagnostic goals can be credited to their efficient implementation of particular disease cells such as proteins and nucleic acids. Moreover, Exosome diagnostic examinations are currently being created for various illnesses like transmissible diseases, neurological disorders and cancer.
The instruments segment holds a major portion of the exosomes diagnostic therapeutic and research tools market share. The expansion of the segment’s market size is propelled by swift breakthroughs in research and development projects in the medical industry. Also, the steady rise in the number of companies producing tools for therapeutic and diagnosis is contributing to the expansion of the segment.
Whereas, the kits and reagents segment is anticipated to lead the Exosome Diagnostics, Therapeutics and Research Tools Market during the estimation period. This is because of the surging need for non-surgical commercially available diagnostic kits. Interestingly, due to the lack of alternatives and the only option of an exosome-based examination made by the ExoDx which offers a test kit for at-home sample collection. Therefore, owing to this only passed and authorised product in the industry, the kits and reagents category will be under monopoly competition by Bio-Techne till 2029.
The cancer segment remained the top category with the maximum market share of exosome diagnostics therapeutics and research tools. Exosomes also serve an essential function in cancer treatment as a transporter of therapeutic load, providing medicines, RNA intrusion molecules or immunomodulatory operatives to aim those tumour cells. Moreover, the segment is further benefited by its ability to identify particular disease molecules in human fluids in case of cancer diagnosis. So, these exosomes perform as a steady source of proteins, cDNAs, miRNAs, circRNAs and tumour-derived antigens which can be applied in the initial diagnosis & prospects of cancer.
North America completely dominated the Exosome Diagnostics, Therapeutics and Research Tools Market in 2023. The region’s expansion is because of propellants like thriving GDP which allowed it to fully support by investing a humungous amount into establishing study and development laboratories with sophisticated systems and apparatus, the existence of top universities such as MIT, Harvard, etc., infusing ample efforts into research and development activities. Further, the United States government’s commitment to facilitating nearly 5 per cent of the yearly healthcare budget for R&D operations, boosts the region’s market share.
Asia-Pacific area is foreseen to be the rapidly growing industry throughout the estimation period. This rise is credited to drivers including a sharp surge in cancer incidences, a huge population, and booming economies of emerging countries i.e. India, Indonesia Vietnam and China as a developed player accelerating the APAC market size.
Bio-Techne (US), ILIAS Biologics Inc. (Korea), NanoFCM Inc. (UK), Evox Therapeutics (US), System Biosciences, LLC. (US), Capricor Therapeutics, Inc. (US), Capital Biosciences, Inc. (US), Exonox Biosciences, Inc. (Taiwan), AMSBIO (UK), INOVIQ (Australia), Kimera Labs (US) NanoSomiX, Inc. (US), Direct Biologics LLC (US), Everzom (France), Regeneus Ltd (Australia), Exogenus Therapeutics (Portugal), CUREXSYS (Germany), RION (US), Aegle Therapeutics (US), Multimmune GmbH (Germany), Mercy Bioanalytics (US) are some of the key market players.
By Type
By Product and Services
By Application
By Region
Frequently Asked Questions
Chronic disease prevalence, biotech advances, personalized medicine, and R&D investments.
Scientific journals, conferences, professional networks, and industry news.
Integration with digital health, novel therapeutics, and academia-industry collaborations.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region